H.C. Wainwright upgraded Outlook Therapeutics to Buy from Neutral with a price target of $2, up from $1. The company announced that it had reached agreement “in principle” with FDA that should allow it to refile the application for ONS-5010 by the end of 2024, potentially enabling approval by mid-2025, the analyst tells investors in a research note. The firm moved up its expected approval for ONS-5010 to mid-2026 and raised the probability of success from 50% to 65%. It cites visibility and the faster path to market for the upgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on OTLK:
- Outlook Therapeutics® Provides Update on Type A Meetings with FDA
- Outlook Therapeutics provides update on Type A meetings with FDA
- Outlook Therapeutics® to Present at Guggenheim’s 5th Annual Inflammation, Neurology & Immunology (INI) Conference
- Outlook Therapeutics® Requests Type A Meeting With FDA
- Outlook Therapeutics requests Type A Meeting with FDA